{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:58Z","timestamp":1792790578435,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K99HL150218"],"award-info":[{"award-number":["K99HL150218"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/012pb6c26","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL135607"],"award-info":[{"award-number":["R01HL135607"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/012pb6c26","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL147124"],"award-info":[{"award-number":["R01HL147124"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/012pb6c26","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["3385-19"],"award-info":[{"award-number":["3385-19"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","id":[{"id":"https:\/\/ror.org\/012pb6c26","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK116944"],"award-info":[{"award-number":["R01DK116944"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","id":[{"id":"https:\/\/ror.org\/012pb6c26","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["LA1_C12-06917"],"award-info":[{"award-number":["LA1_C12-06917"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2019112"],"award-info":[{"award-number":["2019112"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI097320"],"award-info":[{"award-number":["R01AI097320"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI120766"],"award-info":[{"award-number":["R01AI120766"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CRISPR\/Cas9-mediated beta-globin (\n                    <jats:italic>HBB<\/jats:italic>\n                    ) gene correction of sickle cell disease (SCD) patient-derived hematopoietic stem cells (HSCs) in combination with autologous transplantation represents a recent paradigm in gene therapy. Although several Cas9-based\n                    <jats:italic>HBB<\/jats:italic>\n                    -correction approaches have been proposed, functional correction of in vivo erythropoiesis has not been investigated previously. Here, we use a humanized globin-cluster SCD mouse model to study Cas9-AAV6-mediated\n                    <jats:italic>HBB-<\/jats:italic>\n                    correction in functional HSCs within the context of autologous transplantation. We discover that long-term multipotent HSCs can be gene corrected ex vivo and stable hemoglobin-A production can be achieved in vivo from\n                    <jats:italic>HBB<\/jats:italic>\n                    -corrected HSCs following autologous transplantation. We observe a direct correlation between increased\n                    <jats:italic>HBB<\/jats:italic>\n                    -corrected myeloid chimerism and normalized in vivo red blood cell (RBC) features, but even low levels of chimerism resulted in robust hemoglobin-A levels. Moreover, this study offers a platform for gene editing of mouse HSCs for both basic and translational research.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-20909-x","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T06:18:42Z","timestamp":1611901122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7406-0151","authenticated-orcid":false,"given":"Adam C.","family":"Wilkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5966-4803","authenticated-orcid":false,"given":"Daniel P.","family":"Dever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3102-5820","authenticated-orcid":false,"given":"Joab","family":"Camarena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten T.","family":"Charlesworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1317-685X","authenticated-orcid":false,"given":"Chika","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9841-6973","authenticated-orcid":false,"given":"Hiromitsu","family":"Nakauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-4648","authenticated-orcid":false,"given":"Matthew H.","family":"Porteus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"20909_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/17474086.2018.1486703","volume":"11","author":"A Leonard","year":"2018","unstructured":"Leonard, A. & Tisdale, J. F. Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced. Expert Rev. Hematol. 11, 547\u2013565 (2018).","journal-title":"Expert Rev. Hematol."},{"key":"20909_CR2","doi-asserted-by":"publisher","unstructured":"Chabannon, C. et al. Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies. Sci. Transl. Med. 10, https:\/\/doi.org\/10.1126\/scitranslmed.aap9630 (2018).","DOI":"10.1126\/scitranslmed.aap9630"},{"key":"20909_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","volume":"539","author":"DP Dever","year":"2016","unstructured":"Dever, D. P. et al. CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells. Nature 539, 384\u2013389 (2016).","journal-title":"Nature"},{"key":"20909_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/MOH.0000000000000385","volume":"24","author":"DP Dever","year":"2017","unstructured":"Dever, D. P. & Porteus, M. H. The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation. Curr. Opin. Hematol. 24, 481\u2013488 (2017).","journal-title":"Curr. Opin. Hematol."},{"key":"20909_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.exphem.2017.07.006","volume":"54","author":"MC Gundry","year":"2017","unstructured":"Gundry, M. C. et al. Technical considerations for the use of CRISPR\/Cas9 in hematology research. Exp. Hematol. 54, 4\u201311 (2017).","journal-title":"Exp. Hematol."},{"key":"20909_CR6","doi-asserted-by":"publisher","first-page":"360ra134","DOI":"10.1126\/scitranslmed.aaf9336","volume":"8","author":"MA DeWitt","year":"2016","unstructured":"DeWitt, M. A. et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).","journal-title":"Sci. Transl. Med"},{"key":"20909_CR7","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/mt.2016.148","volume":"24","author":"MD Hoban","year":"2016","unstructured":"Hoban, M. D. et al. CRISPR\/Cas9-mediated correction of the sickle mutation in human CD34+ cells. Mol. Ther. 24, 1561\u20131569 (2016).","journal-title":"Mol. Ther."},{"key":"20909_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nprot.2017.143","volume":"13","author":"RO Bak","year":"2018","unstructured":"Bak, R. O., Dever, D. P. & Porteus, M. H. CRISPR\/Cas9 genome editing in human hematopoietic stem cells. Nat. Protoc. 13, 358\u2013376 (2018).","journal-title":"Nat. Protoc."},{"key":"20909_CR9","doi-asserted-by":"publisher","unstructured":"Schiroli, G. et al. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aan0820 (2017).","DOI":"10.1126\/scitranslmed.aan0820"},{"key":"20909_CR10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","volume":"24","author":"G Schiroli","year":"2019","unstructured":"Schiroli, G. et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell 24, 551\u2013565 (2019).","journal-title":"Cell Stem Cell"},{"key":"20909_CR11","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas, C. A. et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med. 24, 1216\u20131224 (2018).","journal-title":"Nat. Med."},{"key":"20909_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1126\/science.278.5339.873","volume":"278","author":"TM Ryan","year":"1997","unstructured":"Ryan, T. M., Ciavatta, D. J. & Townes, T. M. Knockout-transgenic mouse model of sickle cell disease. Science 278, 873\u2013876 (1997).","journal-title":"Science"},{"key":"20909_CR13","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.278.5339.876","volume":"278","author":"C P\u00e1szty","year":"1997","unstructured":"P\u00e1szty, C. et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278, 876\u2013878 (1997).","journal-title":"Science"},{"key":"20909_CR14","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2006-02-004812","volume":"108","author":"LC Wu","year":"2006","unstructured":"Wu, L. C. et al. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 108, 1183\u20131188 (2006).","journal-title":"Blood"},{"key":"20909_CR15","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1126\/science.1152092","volume":"318","author":"J Hanna","year":"2007","unstructured":"Hanna, J. et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318, 1920\u20131923 (2007).","journal-title":"Science"},{"key":"20909_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-019-1244-x","volume":"571","author":"AC Wilkinson","year":"2019","unstructured":"Wilkinson, A. C. et al. Long-term ex vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation. Nature 571, 117\u2013121 (2019).","journal-title":"Nature"},{"key":"20909_CR17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41596-019-0263-2","volume":"15","author":"AC Wilkinson","year":"2020","unstructured":"Wilkinson, A. C., Ishida, R., Nakauchi, H. & Yamazaki, S. Long-term ex vivo expansion of mouse hematopoietic stem cells. Nat. Protoc. 15, 628\u2013648 (2020).","journal-title":"Nat. Protoc."},{"key":"20909_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nbt.3198","volume":"33","author":"VT Chu","year":"2015","unstructured":"Chu, V. T. et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 33, 543\u2013548 (2015).","journal-title":"Nat. Biotechnol."},{"key":"20909_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-016-0234-4","volume":"16","author":"VT Chu","year":"2016","unstructured":"Chu, V. T. et al. Efficient generation of Rosa26 knock-in mice using CRISPR\/Cas9 in C57BL\/6 zygotes. BMC Biotechnol. 16, 4 (2016).","journal-title":"BMC Biotechnol."},{"key":"20909_CR20","doi-asserted-by":"publisher","unstructured":"Sharma, R. et al. TRACE-Seq reveals clonal reconstitution dynamics of gene targeted human hematopoietic stem cells. bioRxiv, https:\/\/doi.org\/10.1101\/2020.05.25.115329 (2020).","DOI":"10.1101\/2020.05.25.115329"},{"key":"20909_CR21","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41587-020-0551-y","volume":"38","author":"S Ferrari","year":"2020","unstructured":"Ferrari, S. et al. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nat. Biotechnol. 38, 1298\u20131308 (2020).","journal-title":"Nat. Biotechnol."},{"key":"20909_CR22","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1182\/blood-2003-04-1251","volume":"102","author":"DN Levasseur","year":"2003","unstructured":"Levasseur, D. N., Ryan, T. M., Pawlik, K. M. & Townes, T. M. Correction of a mouse model of sickle cell disease: lentiviral\/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102, 4312\u20134319 (2003).","journal-title":"Blood"},{"key":"20909_CR23","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nbt.3584","volume":"34","author":"R Palchaudhuri","year":"2016","unstructured":"Palchaudhuri, R. et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat. Biotechnol. 34, 738\u2013745 (2016).","journal-title":"Nat. Biotechnol."},{"key":"20909_CR24","doi-asserted-by":"publisher","first-page":"12169","DOI":"10.1073\/pnas.1509158112","volume":"112","author":"N Keleku-Lukwete","year":"2015","unstructured":"Keleku-Lukwete, N. et al. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation. Proc. Natl Acad. Sci. USA 112, 12169\u201312174 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"20909_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.omtn.2018.04.017","volume":"12","author":"CT Charlesworth","year":"2018","unstructured":"Charlesworth, C. T. et al. Priming human repopulating hematopoietic stem and progenitor cells for Cas9\/sgRNA gene targeting. Mol. Ther. Nucleic Acids 12, 89\u2013104 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"20909_CR26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.stem.2019.04.001","volume":"24","author":"RM Martin","year":"2019","unstructured":"Martin, R. M. et al. Highly efficient and marker-free genome editing of human pluripotent stem cells by CRISPR-Cas9 RNP and AAV6 donor-mediated homologous recombination. Cell Stem Cell 24, 821\u2013828 (2019).","journal-title":"Cell Stem Cell"},{"key":"20909_CR27","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","volume":"130","author":"CD Fitzhugh","year":"2017","unstructured":"Fitzhugh, C. D. et al. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood 130, 1946\u20131948 (2017).","journal-title":"Blood"},{"key":"20909_CR28","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3324\/haematol.2019.227561","volume":"105","author":"A Magnani","year":"2020","unstructured":"Magnani, A. et al. Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy. Haematologica 105, 1240\u20131247 (2020).","journal-title":"Haematologica"},{"key":"20909_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","volume":"312","author":"BP Yawn","year":"2014","unstructured":"Yawn, B. P. et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 312, 1033\u20131048 (2014).","journal-title":"JAMA"},{"key":"20909_CR30","doi-asserted-by":"publisher","unstructured":"Belcher, J. D., Nath, K. A. & Vercellotti, G. M. Vasculotoxic and proinflammatory effects of plasma heme: cell signaling and cytoprotective responses. ISRN Oxidative Med. 2013, https:\/\/doi.org\/10.1155\/2013\/831596 (2013).","DOI":"10.1155\/2013\/831596"},{"key":"20909_CR31","doi-asserted-by":"publisher","first-page":"15045","DOI":"10.1038\/mtm.2015.45","volume":"2","author":"TI Pestina","year":"2015","unstructured":"Pestina, T. I. et al. Amelioration of murine sickle cell disease by nonablative conditioning and \u03b3-globin gene-corrected bone marrow cells. Mol. Ther. Methods Clin. Dev. 2, 15045 (2015).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"20909_CR32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4916.4916","volume":"124","author":"J Nguyen","year":"2014","unstructured":"Nguyen, J. et al. Phenotypic characterization the Townes sickle mice. Blood 124, 4916 (2014).","journal-title":"Blood"},{"key":"20909_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09614-y","volume":"10","author":"M Pavel-Dinu","year":"2019","unstructured":"Pavel-Dinu, M. et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat. Commun. 10, 1634 (2019).","journal-title":"Nat. Commun."},{"key":"20909_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11962-8","volume":"10","author":"N Gomez-Ospina","year":"2019","unstructured":"Gomez-Ospina, N. et al. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. Nat. Commun. 10, 4045 (2019).","journal-title":"Nat. Commun."},{"key":"20909_CR35","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1126\/science.aat7873","volume":"362","author":"R Yamamoto","year":"2018","unstructured":"Yamamoto, R., Wilkinson, A. C. & Nakauchi, H. Changing concepts in hematopoietic stem cells. Science 362, 895\u2013896 (2018).","journal-title":"Science"},{"key":"20909_CR36","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1182\/blood-2011-05-353201","volume":"119","author":"S Takagi","year":"2012","unstructured":"Takagi, S. et al. Membrane-bound human SCF\/KL promotes in vivo human hematopoietic engraftment and myeloid differentiation. Blood 119, 2768\u20132777 (2012).","journal-title":"Blood"},{"key":"20909_CR37","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/leu.2010.158","volume":"24","author":"M Wunderlich","year":"2010","unstructured":"Wunderlich, M. et al. AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24, 1785\u20131788 (2010).","journal-title":"Leukemia"},{"key":"20909_CR38","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/nm.4103","volume":"22","author":"A Reinisch","year":"2016","unstructured":"Reinisch, A. et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat. Med. 22, 812\u2013821 (2016).","journal-title":"Nat. Med."},{"key":"20909_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1172\/JCI89364","volume":"127","author":"A Abarrategi","year":"2017","unstructured":"Abarrategi, A. et al. Versatile humanized niche model enables study of normal and malignant human hematopoiesis. J. Clin. Invest. 127, 543\u2013548 (2017).","journal-title":"J. Clin. Invest."},{"key":"20909_CR40","doi-asserted-by":"publisher","unstructured":"Bai, T. et al. Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-019-0601-5 (2019).","DOI":"10.1038\/s41591-019-0601-5"},{"key":"20909_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gde.2020.05.035","volume":"64","author":"AC Wilkinson","year":"2020","unstructured":"Wilkinson, A. C. & Nakauchi, H. Stabilizing hematopoietic stem cells in vitro. Curr. Opin. Genet. Dev. 64, 1\u20135 (2020).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"20909_CR42","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","volume":"6","author":"M Eapen","year":"2019","unstructured":"Eapen, M. et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 6, e585\u2013e596 (2019).","journal-title":"Lancet Haematol."},{"key":"20909_CR43","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1182\/bloodadvances.2017009449","volume":"1","author":"Y Huo","year":"2017","unstructured":"Huo, Y. et al. Allogeneic bone marrow transplant in the absence of cytoreductive conditioning rescues mice with \u03b2-thalassemia major. Blood Adv. 1, 2421\u20132432 (2017).","journal-title":"Blood Adv."},{"key":"20909_CR44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nbt.4021","volume":"36","author":"MD Canny","year":"2018","unstructured":"Canny, M. D. et al. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency. Nat. Biotechnol. 36, 95\u2013102 (2018).","journal-title":"Nat. Biotechnol."},{"key":"20909_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10735-7","volume":"10","author":"R Jayavaradhan","year":"2019","unstructured":"Jayavaradhan, R. et al. CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites. Nat. Commun. 10, 2866 (2019).","journal-title":"Nat. Commun."},{"key":"20909_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15845-1","volume":"11","author":"B Wienert","year":"2020","unstructured":"Wienert, B. et al. Timed inhibition of CDC7 increases CRISPR-Cas9 mediated templated repair. Nat. Commun. 11, 2109 (2020).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-20909-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-20909-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-20909-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T05:17:03Z","timestamp":1669958223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-20909-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["20909"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-20909-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.10.13.338319","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"5 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.N. is a co-founder and shareholder in ReproCELL, Megakaryon, and Century Therapeutics. M.H.P. has equity and serves on the scientific advisory board of CRISPR Therapeutics and Allogene Therapeutics. However, none of these companies had input into the design, execution, interpretation, or publication of the work in this manuscript. All other authors do not declare any competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"686"}}